DMAC logo

DMAC DiaMedica Therapeutics Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$8.25
+0.23 (+2.87%)

DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 d…

Market Cap: $445.15Mwww.diamedica.com

Price

No data yet.

Social Signal Score

50
5d
—
30d
50
3 mentions
—
60d
50
3 mentions
—
90d
50
4 mentions
—
news: 4

Analyst Ratings

6 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 0Sell 0Strong Sell 0
Avg price target$8.33+1.0%
Low $7Median $8High $10
Current Consensus

Revenue

$0.00
$-3.7K$165.4K$334.6K$503.7K
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-0.68
$-0.75–$-0.57
4 analysts
FY2026
$-0.78
$-0.82–$-0.73
3 analysts
FY2027
$-0.71
$-0.75–$-0.68
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Dietrich John Pauls
Sector
Healthcare
Industry
Biotechnology
Employees
35
Beta
0.94
Country
US
Piotroski score
1 / 9 (Weak)
Altman Z-score
24.99
www.diamedica.com